

May 19th, 2026

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, C-1,
Block G, Bandra Kurla Complex,
Bandra (E), Mumbai 400051

NSE SYMBOL: INVICTA**ISIN: INE0XJ501010****Subject: Intimation Under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)****Dear Sir/Madam,**

In reference to the captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held on Monday, May 18th, 2026, has considered and approved the Audited Financial Results (Standalone and Consolidated) of the Company for the Half Year and Financial Year ended March 31, 2026 (“Financial Results”).

A detailed press release in this effect is enclosed for your information and records.

You are requested to take the same on record.

Thanking you,

Yours Faithfully,

For Invicta Diagnostic Limited

Sanket Vinod Jain
Chairman and Non-Executive Director
DIN: 08299039
Place: Mumbai



Invicta Diagnostic Limited Reports FY26 Total Income of ₹33.04 Cr with EBITDA Margins Above 30%

Mumbai – May 19th, 2026 Invicta Diagnostic Limited (NSE - INVICTA), – one of the leading diagnostic service providers in Maharashtra’s healthcare services sector, has announced its Audited Financial Results for H2 FY26

Key Consolidated Financial Highlights

H2 FY26

- Total Income of ₹ 15.96 Cr
- EBITDA of ₹ 3.55 Cr
- EBITDA Margin of 22.24%
- Net Profit of ₹ 0.79 Cr
- Net Profit Margin of 4.94%
- EPS of ₹ 0.79

FY26

- Total Income increased to ₹ 33.04 Cr from ₹ 30.18 Cr annually
- EBITDA increased to ₹ 10.45 Cr from ₹ 9.29 Cr annually
- EBITDA Margins increased to 31.63% from 30.78%
- Net Profit of ₹ 4.87 Cr
- Net Profit Margin of 14.74%
- EPS of ₹ 4.90

During FY26, the Company continued to invest towards its long-term growth strategy and network expansion, resulting in cash outflow of ₹12.96 Cr towards purchase of fixed assets. Depreciation expense increased by approximately 31% to ₹3.25 Cr in FY26 from ₹2.49 Cr in FY25, primarily reflecting higher asset base during the year. As newly added centres continue to mature and scale up operations, the Company expects stronger revenue contribution and improved operating leverage in the coming periods.

H2 FY26 Key Operational Highlights

Strategic Entry into Pune Through Joint Venture	<ul style="list-style-type: none">• Entered Pune market through a strategic JV with four prominent radiologists• Company holds 52% stake ensuring management, control and operational oversight• Evaluating opportunities to establish additional diagnostic centres in Pune over next 1 to 2 years, subject to market opportunities and Board approvals• First centre secured at Market Yard, Pune with 2,425 sq. ft. leased property• Upcoming centre to offer MRI, CT scan, Mammography, Digital X-Ray and integrated Pathology services
--	---

<p style="text-align: center;">Dadar Centre Commences Commercial Operations</p>	<ul style="list-style-type: none"> • Commenced commercial operations at Dadar Centre from 30th January 2026 • Expanded advanced diagnostics portfolio with PET-CT, CT scan, Sonography, Pathology and X-Ray services • Strategically located near Tata Memorial Hospital within a high-demand oncology diagnostics cluster • Centre established with project investment of approximately ₹5.50 Cr
<p style="text-align: center;">Strategic Acquisition Marks Entry into Nashik</p>	<ul style="list-style-type: none"> • Received Board and Shareholders' approval to acquire up to 95% stake in Vinchurkar Diagnostics Private Limited. • Successfully completed the first phase of strategic acquisition on 8 May 2026, by securing a 51% controlling stake in Vinchurkar Diagnostics Private Limited. • Marks strategic entry beyond Mumbai Metropolitan Region into Nashik healthcare market • Acquisition to be completed in phased manner with total consideration of ₹7.60 Cr

Commenting on the Performance, Mr. Sanket Vinod Jain, Chairman and Non-Executive Director of Invicta Diagnostic Limited, said, “FY26 has been a landmark year for Invicta Diagnostic Limited as we successfully completed our NSE Emerge listing in December 2025 and concluded the year with a stable financial and operational performance. During FY26, we reported Total Income of ₹33.04 Cr and maintained EBITDA margins in excess of 30%, reflecting strong operating efficiency and disciplined execution.

During the second half of the year, we expanded our presence through our strategic entry into Pune with plans for advanced diagnostic centres, commenced operations at our Dadar Centre with PET-CT and CT Scan facilities near Tata Memorial Hospital, and received Board and Shareholders' approval to acquire up to 95% stake in Vinchurkar Diagnostics Private Limited in Nashik, strengthening our platform for long term growth across Maharashtra. These investments are expected to support higher scale, improved operational reach, and stronger growth momentum in the coming years.

As we enter FY27, we remain focused on expanding our diagnostics network, strengthening our service portfolio, and driving sustainable growth while maintaining operational efficiency. We remain optimistic about the opportunities ahead and are confident of building on this momentum in the coming years.”

About Invicta Diagnostic Limited

Invicta Diagnostic Limited is a diagnostic services company operating in the Mumbai Metropolitan Region, providing radiology and pathology solutions under its consumer facing brand, **PC Diagnostics**.

Through the PC Diagnostics brand, the Company offers a comprehensive range of diagnostic services, including radiology and imaging, pathology and clinical laboratory testing, and teleradiology. Its operations are supported by a structured hub and spoke model designed to ensure efficiency, reach, and patient convenience.

The Company's **network comprises 8 diagnostic centers and one centralized laboratory across the MMR region in Maharashtra**. This includes one flagship hub in Thane with full testing capabilities, three additional hub centres offering advanced and basic diagnostics, and three spoke centres focused on basic diagnostics and sample collection, supported by a centralized laboratory.

Invicta Diagnostic Limited places strong emphasis on patient convenience through services such as home sample collection, house calls, and multiple report delivery options. The Company continues to strengthen its presence in MMR while expanding across Maharashtra's diagnostic market, guided by its focus on quality, affordability, and consistent patient care.

The company was listed on NSE Emerge on 8th December 2025.

In FY26, the Company recorded a consolidated revenue of ₹ 33.04 Cr, an EBITDA of ₹ 10.45 Cr, and a net profit of ₹ 4.87 Cr.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor



Kirin Advisors Private Limited

Sunil Mudgal - Director

sunil@kirinadvisors.com

+91 98692 75849

www.kirinadvisors.com